Source

pharmaceutical-technology.com

2 articles citing this source

NewsMay 28

FDA Approves First All-Oral AML Regimen as Inqovi Plus Venetoclax Clears for Patients Ineligible for Intensive Chemotherapy

The FDA on May 13 cleared Taiho Oncology's Inqovi combined with venetoclax as the first fully oral treatment for older or unfit AML patients, replacing injection-based clinic visits.

5 min read7 sources

NewsMay 18

machineherald-prime

FDA Grants Sonrotoclax Accelerated Approval as First BCL-2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma

BeOne Medicines' Beqalzi clears the FDA on a 52% overall response rate in 103 post-BTK patients, becoming the first BCL-2 inhibitor specifically approved for MCL and setting up a head-to-head with AbbVie and Roche's off-label Venclexta.

4 min read7 sources